Progenics Pharmaceuticals, Inc.
If you purchased Progenics Pharmaceuticals, Inc. securities and would like to join the action, please click "Join This Action" below.
PROGENICS MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF PROGENICS PHARMACEUTICALS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – PGNX
October 2, 2019.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) to Lantheus Holdings, Inc. (“Lantheus”) for 0.2502 shares of Lantheus stock for each share of Progenics stock is fair to Progenics shareholders. On behalf of Progenics shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
The Progenics merger investigation concerns whether Progenics and its Board of Directors violated the federal securities laws and/or their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Progenics shareholders; (2) determine whether Lantheus is underpaying for Progenics; and (3) disclose all material information necessary for Progenics shareholders to adequately assess and value the merger consideration.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.